Table 2.
Overview of included treatment trials
| Study (reference) | Setting | Renal function at enrollment (intervention/control)a | Intervention | Control | No. of participants (intervention/control) | Outcomes assessed |
|---|---|---|---|---|---|---|
| Allgren 1997 (22) | ATN caused by ischemic or nephrotoxic insults | 4.40 ± 1.70 (oliguric subgroup), 4.40 ± 1.40 (nonoliguric subgroup)/ 5.00 ± 2.60 (oliguric subgroup), 4.50 ± 1.70 (nonoliguric subgroup) | Anaritide infusion at 0.05 to 0.20 μg/kg/min for 24 h | Placebo | 243/225 | Need for RRT, mortality, end of study creatinine, and adverse events |
| Herbert 1999 (26) | ATN after major abdominal surgery | 2.80 ± 0.24/2.93 ± 0.38 | Urodilatin infusion at 20 ng/kg/min for 4-6 days | Placebo | 6/6 | Need for RRT, mortality, end of study creatinine, and adverse events |
| Kuse 1996 (29) | Liver transplantation (recipients with refractory oliguria, increase of serum creatinine to at least 200% of preoperative values, and BUN levels ≥70 mg/dl) | 2.02 ± 1.43/2.30 ± 1.14 | Urodilatin at 20 ng/kg/min for 7 h | Placebo | 5/4 | Need for RRT, mortality, and adverse events |
| Lewis 2000 (31) | Oliguric ATN | 8/5.1 (SD not available) | Anaritide infusion at 0.05 to 0.20 μg/kg/min for 24 h | Placebo | 108/114 | Need for RRT, mortality, and adverse events |
| Meyer 1997 (32) | Cardiac surgery (patients post surgery with oliguria) | 2.58 ± 0.70/2.77 ± 0.51 | Urodilatin at 20 ng/kg/min for 7 days | Placebo | 7/7 | Need for RRT, mortality, end of study creatinine, and adverse events |
| Meyer 1999 (33) | After major (cardiac, transplantation) surgery (patients with oliguria) | 9 ± 8/10 ± 16* | One of the 4 Ularitide doses (5 or 20 or 40 or 80 ng/kg/min) for 5 days | Placebo | 114/58 | Need for RRT, mortality, and adverse events |
| Rahman 1994 (34) | ATN | 9 ± 2/9 ± 2* | h-ANP either intrarenal (0.08 μg/kg/min for 8 h) or intravenous (0.20 μg/kg/min for 24 h) along with intravenous furosemide or mannitol | Intravenous furosemide or mannitol | 30/23 | Need for RRT, mortality, and adverse events |
| Sward 2004 (39) | AKI after cardiopulmonary bypass | 1.23 ± 0.04/1.24 ± 0.04 | Recombinant h-ANP at 50 ng/kg/min given for approximately 5 days | Placebo | 29/30 | Need for RRT, mortality, length of ICU stay, and adverse events |
ANP, atrial natriuretic peptide; ATN, acute tubular necrosis; BUN, blood urea nitrogen; ICU, intensive care unit; RRT, renal replacement therapy.
a
Baseline renal function are measured by serum creatinine (mg/dl), except those with asterisks, which are creatinine clearance values (ml/min).